Concepedia

Jonathan Golas

JG

Statistics

Publications

9

Citations

1.6K

H-Index

9

Active since

2004

Affiliations

Pfizer (United States)(Current)

Connecticut Sea Grant

Pearl River Community College

Jonathan Golas is an author at Pfizer (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

2004–2021

9

Publications

9

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Sridhar K. Rabindran, Carolyn Discafani, Edward Rosfjord et al. · Cancer Research · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Hwei‐Ru Tsou, Elsebe G. Overbeek-Klumpers, William Hallett et al. · Journal of Medicinal Chemistry · 2005 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

Matthew Sung, Xingzhi Tan, Bingwen Lu et al. · Molecular Cancer Therapeutics · 2017 · 208 citations

Medicine, Oncology, Pharmacology +17

SKI-606, a Src/Abl Inhibitor with<i>In vivo</i>Activity in Colon Tumor Xenograft Models

Jennifer M. Golas, Judy Lucas, Carlo Etienne et al. · Cancer Research · 2005 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17

Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors

Changhua Ji, Marc D. Roy, Jonathan Golas et al. · Clinical Cancer Research · 2019 · 121 citations

Life Sciences, Immunology, Pharmacology +17

1–5 of 9